ReFacto®1and Advate®2: a single-dose, randomized, two-period crossover pharmacokinetics study in subjects with haemophilia A-Reference-Cited by-同舟云学术

ReFacto®1and Advate®2: a single-dose, randomized, two-period crossover pharmacokinetics study in subjects with haemophilia A

Published:2007-01-25 Issue:2 Volume:13 Page:124-130
ISSN:1351-8216
Container-title:Haemophilia
language:en
Short-container-title:

Author:

DI PAOLA J.,SMITH M. P.,KLAMROTH R.,MANNUCCI P. M.,KOLLMER C.,FEINGOLD J.,KESSLER C.,POLLMANN H.,MORFINI M.,UDATA C.,ROTHSCHILD C.,HERMANS C.,JANCO R.

Publisher

Wiley

Subject

Genetics(clinical),Hematology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2516.2006.01420.x/fullpdf

Reference17 articles.

1. Preclinical pharmacology of albumin-free, B-domain deleted recombinant factor VIII;Brinkhous;Semin Thromb Hemost,2002

2. A large region (approximately equal to 95 kDa) of human factor VIII is dispensable for in vitro procoagulant activity;Toole;Proc Natl Acad Sci U S A,1986

3. Structural and functional characterization of B-domain deleted recombinant factor VIII;Sandberg;Semin Hematol,2001

4. B-domain deleted recombinant factor VIII preparations are bioequivalent to a monoclonal antibody purified plasma-derived factor VIII concentrate: a randomized, three-way crossover study;Kessler;Haemophilia,2005

5. Second generation, B-domain deleted recombinant factor VIII;Berntorp;Thromb Haemost,1997

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cellular stress and coagulation factor production: when more is not necessarily better;Journal of Thrombosis and Haemostasis;2023-12

2. Hemophilia A: Diagnosis and Management;Congenital Bleeding Disorders;2023

3. Ectopic clotting factor VIII expression and misfolding in hepatocytes as a cause for hepatocellular carcinoma;Molecular Therapy;2022-12

4. Area under the curve: Comparing the value of factor VIII replacement therapies in haemophilia A;Haemophilia;2022-11-29

5. Clinical outcome and adherence rate in Scandinavian patients with intermediate‐intensity prophylaxis before and after the switch of standard half‐life FVIII products to BAY 81–8973;Haemophilia;2022-01-10